Back

Login or Register
to download FREE PDF book

Existing user LOGIN
OR
New user REGISTRATION

Register Fill in details Download

Register Fill in details Download

Your download has started.

If the download didn't start automatically, then please click here.

Thank you for the interest in
Drug-Induced Liver Injury

We welcome your feedback on this publication.

Explore more publications

PUBLICATIONS

Sale!

Drug-Induced Liver Injury

(For e-learning course see below) -- Drug-induced liver injury (DILI) is a growing challenge because of the ever- increasing number of drugs used in medical care. DILI is rare but can be serious and is largely unpredictable. It is an important cause of mortality and liver transplantation, and a leading cause of attrition in drug development. Progress is under way in identifying genetic risk factors, exploring new mechanistic concepts of the complex underlying interactions, and developing new bio Read more...
  • Out of Stock
  • isbn: 978-929036099-5
  • Year of publication: 2020
  • Number of pages: 160
  • SKU: 6819

Paperback

At reduced price to increase access. Postage will be added.

Now just

1 00 CHF

Amount:


"Drug-Induced Liver Injury" reviews

There are no reviews yet.

×

Please leave your review for Drug-Induced Liver Injury

Be the first to review “Drug-Induced Liver Injury”

Your email address will not be published.

The maximum upload file size: 300 MB. You can upload: image. Links to YouTube, Facebook, Twitter and other services inserted in the comment text will be automatically embedded. Drop file here

(For e-learning course see below) — Drug-induced liver injury (DILI) is a growing challenge because of the ever- increasing number of drugs used in medical care. DILI is rare but can be serious and is largely unpredictable. It is an important cause of mortality and liver transplantation, and a leading cause of attrition in drug development. Progress is under way in identifying genetic risk factors, exploring new mechanistic concepts of the complex underlying interactions, and developing new biomarkers that can predict or diagnose DILI. The pharmaceutical industry has a key role in advancing these initiatives, and prospective DILI registries must adopt standard procedures for biological sample collection and storing. There is a strong need for standard guidelines to support these efforts.

The consensus report of the CIOMS DILI Working Group aims to provide a critical framework and essential set of tools to detect, diagnose and manage DILI during drug development and in the post-marketing setting. The report is intended for clinical and basic pharmaceutical industry investigators who capture, analyze and communicate liver safety data in drug development. It is also intended for regulatory scientists and expert consultants who comprehensively evaluate new products and emerging biomarkers for their association with DILI risk, and for health care professionals who monitor and manage patients treated with potentially hepatotoxic drugs in clinical practice.

Case report form (Excel) Supplemental Appendices

—————-

CIOMS/UMC e-learning course, released in May 2022 on the website of the Uppsala Monitoring Centre (UMC): This course is based on the sections of the CIOMS consensus report most relevant to the post-marketing setting and clinical care. Please note that for the time being this training is available only for national pharmacovigilance centres and other public sector participants. UMC is planning to extend the availability to other parties in the near future.
Access the training here.

Webinar (Shanghai) held 20 November 2020: Programme and speakers’ details  |  Video recordings (English and Chinese); requires updated browser, e.g. Firefox

Webinar (Singapore) held 20 July 2020: Video  |  Slides


You may also like…